The intricate relationship between gut microbial dysbiosis and metabolic reprogramming, specifically involving bile acids (BAs), represents a critical frontier in understanding the pathogenesis of Ulcerative Colitis (UC) and Crohn's Disease (CD). Recent systematic profiling of these components has provided a roadmap for identifying novel biomarkers and therapeutic targets. As a dedicated partner in Live Biotherapeutic Product (LBP) development, Creative Biolabs offers a comprehensive suite of analytical and experimental services designed to bridge the gap between large-scale clinical observations and mechanistic validation. By integrating high-resolution microbial sequencing with targeted metabolomics, we empower researchers to translate complex data into actionable therapeutic strategies. Contact our scientific team today for a technical consultation or a customized project quotation.
Overview: Intestinal Dysbiosis and Bile Acid Profile Alterations in UC and CD Patients1
The study titled "Gut microbiota and bile acids profiles study of ulcerative colitis and Crohn's disease patients" systematically investigates the distinct and overlapping signatures of microbial communities and bile acid compositions in patients with IBD compared to healthy controls (HC). IBD, comprising UC and CD, is characterized by chronic intestinal inflammation. While the role of the gut microbiota in IBD is well-documented, the specific metabolic consequences, particularly regarding the transformation of primary bile acids into secondary bile acids by microbial enzymes, require high-resolution profiling to distinguish between UC and CD phenotypes.
Experimental Methodology
-
Microbial Profiling: 16S rRNA gene sequencing and metagenomic shotgun sequencing were performed on fecal and mucosal biopsy samples to establish taxonomy and functional gene potential.
-
Metabolomic Quantitation: Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) was applied for the absolute quantification of primary, secondary, conjugated, and unconjugated bile acid fractions in fecal and serum samples.
-
Statistical Correlation Analysis: Spearman's rank correlation and canonical correspondence analyses were leveraged to map specific bacterial taxa against altered bile acid species and clinical inflammatory indices (e.g., fecal calprotectin, Mayo score, CDAI).
Key Findings
-
Microbial Dysbiosis: Both UC and CD patients exhibited a significant reduction in microbial diversity. Specifically, a depletion of butyrate-producing bacteria (e.g., Faecalibacterium prausnitzii) and an enrichment of Protoproteobacteria were observed.
-
Bile Acid Alterations: IBD patients showed a marked decrease in secondary bile acids and an accumulation of primary and conjugated bile acids. The ratio of secondary to primary bile acids was significantly lower in the CD group compared to the UC group.
-
Microbe-BA Correlation: Strong correlations were identified between the loss of specific taxa (such as Bacteroides and Clostridium clusters) and the diminished levels of deoxycholic acid (DCA) and lithocholic acid (LCA), suggesting a failure in microbial bile salt hydrolase (BSH) and 7α-dehydroxylation activities.
The research concludes that the gut microbiota-bile acid axis is significantly disrupted in IBD, with CD presenting a more profound metabolic shift than UC. These distinct profiles suggest that BA-modulating LBPs could serve as a targeted intervention strategy for restoring intestinal homeostasis.
Mapping R&D Bottlenecks to Full-Service CRO Solutions
Replicating, validating, or therapeutic targeting of the microbial-metabolic axes described in this research requires specialized, high-throughput workflows. Creative Biolabs translates these complex clinical research findings into systematic, executable CRO service modules to support downstream live biotherapeutic and biomarker discovery programs.
Next-Generation Sequencing (NGS) Platforms
Bile Acid Metatranscriptomics & Quantitation
-
Targeted Bile Acid Profiling utilizing state-of-the-art LC-MS/MS systems.
-
Absolute quantification of over 40 distinct primary, secondary, free, and conjugated bile acid species.
-
High-sensitivity assays tailored for low-volume clinical or preclinical animal model samples (feces, serum, bile, intestinal contents).
In Vitro & In Vivo Functional Screening
Ready-to-Use Research Products and Reference Strains
To support the practical application of these findings, Creative Biolabs provides a specialized catalog of research-grade products. These are specifically curated for researchers aiming to develop LBPs or study the BA axis.
-
BA-Transforming Strains: Standardized cultures of Bacteroides fragilis, Clostridium spp., and Lactobacillus species known for high BSH activity.
-
Next-Generation Probiotics (NGPs): High-viability samples of Faecalibacterium prausnitzii and Akkermansia municiphila, which are frequently reported as depleted in the study's UC/CD cohorts.
The Creative Biolabs Platform Advantages
Navigating the strict requirements of anaerobic biotechnology and strict regulatory criteria requires an industrial-grade service infrastructure. Creative Biolabs provides unique technical capabilities that set us apart as a premium global CRO:
Strict Anaerobic Excellence
We maintain a world-class anaerobic workstation environment, essential for the isolation and characterization of the oxygen-sensitive species (e.g., Firmicutes) highlighted in IBD research.
Standardized Metabolic Phenotyping
Our metabolite extraction protocols are specifically optimized for fecal and intestinal tissue matrices, minimizing matrix interference and maximizing the recovery of hydrophobic bile acids.
Regulatory-Ready LBP Development
We transition your research from the lab to the clinic. Our services encompass strain identification, safety assessment (AMR profiling), and pilot-scale fermentation under rigorous quality control.
Integrated "One-Stop" Solutions
From initial clinical sample sequencing to the final validation of a candidate LBP in a mouse model, we provide a seamless workflow that reduces technical variability and accelerates timelines.
Primary Applied Fields of Microbiome-Bile Acid Axis Research
-
Live Biotherapeutic Product (LBP) Engineering: Design and optimization of multi-strain consortia or genetically modified microbial platforms targeting targeted restoration of BSH activity or anti-inflammatory secondary BA production in the gut.
-
Fecal Microbiota Transplantation (FMT) Standardization: Comprehensive screening of donor fecal materials to verify optimal microbiome-metabolite profiles before clinical manufacturing and deployment.
-
Biomarker Discovery & Stratification: Development of non-invasive diagnostic or prognostic panels using combined microbial taxonomies and bile acid ratios to track disease flare-ups and patient response to targeted biologics.
-
Functional Food & Nutraceutical Formulation: Designing precise prebiotic or symbiotic ingredients aimed at enriching endogenous BSH-active bacterial populations within compromised hosts.
Project Inquiries
Deciphering the fine balance between the intestinal microbiota and bile acid profiling represents a critical milestone in understanding IBD pathogenesis and establishing effective intervention strategies for Ulcerative Colitis and Crohn's Disease. Overcoming the technical complexities of absolute metabolite quantification and high-throughput anaerobic strain validation requires reliable, industrial-grade technological solutions. Creative Biolabs remains committed to delivering state-of-the-art CRO services and analytical pipelines tailored to your specific exploratory milestones. Streamline your microbiome and drug discovery programs by leveraging our specialized infrastructure.
Ready to advance your IBD research? Contact our technical team today to discuss your project requirements or to request a formal quotation for our sequencing and metabolomics services. Let us be the expert extension of your laboratory.
Frequently Asked Questions (FAQs)
How do you ensure the stability of bile acids in fecal samples during transport?
Bile acids are relatively stable, but microbial activity can continue post-sampling. We provide specialized collection kits with stabilizers or recommend flash-freezing in liquid nitrogen to "lock" the metabolic profile at the moment of collection.
Can your sequencing platform distinguish between closely related species involved in BA metabolism?
Yes. While 16S sequencing provides genus-level insights, our Shotgun Metagenomic Sequencing provides species-level and even strain-level resolution, allowing for the identification of specific functional genes (like cbh or bai genes) responsible for bile acid transformation.
Can your bioinformatic pipelines correlate specific metagenomic shotgun data with targeted LC-MS/MS bile acid concentrations?
Yes. We deploy integrated multi-omic correlation analysis using advanced statistical modules (such as MaAsLin2 and customized network analyses) to establish direct mathematical links between the relative abundance of microbial functional genes (e.g., cbh, baiA, baiB) and absolute concentrations of bile acid metabolites.
Reference
-
Wang, Zhejiong et al. "Gut microbiota and bile acids profiles study of ulcerative colitis and Crohn's disease patients." Frontiers in microbiology 17 1782415. 7 Apr. 2026, doi:10.3389/fmicb.2026.1782415. Distributed under Open Access license CC BY 4.0, without modification.
